We’re halfway through our Empowering Progress Match Campaign to fund critical neuroendocrine cancer research. With a remarkable 33% increase in funding requests in the last year alone, we can't afford to let life-changing research go unfunded.
From now until June 30, when you donate to NETRF, your gift* is doubled, up to $50,000, thanks to a generous match from NETRF board member Steve Kaufer. When Steve lost his first wife, Caroline, to neuroendocrine cancer at the age of 42, he dedicated himself to investing in NETRF research to find better treatment options and cures.
"We must accelerate neuroendocrine cancer innovations," said Steve.
Please join Steve in his commitment to funding research to develop better treatments and, ultimately, a cure for neuroendocrine cancer.
We can't leave potential life-changing research unfunded.
Make your gift today and double your impact!
*Excludes Everlasting Impact Tributes and Community Fundraising gifts
| |
KNOW YOUR NETs is July 20
Our annual KNOW YOUR NETs Virtual Patient Education Conference is on Saturday, July 20.
Registration is open here, where you can also view the entire day's agenda.
We're talking about Hope in Action, covering topics you want to learn more about, such as symptom management and nutrition, genetics and fertility, clinical trials, immunotherapy, and more!
Don't miss out! Register below.
| |
NETWise Episode 1: What You Need to Know About NETs & NECs - UPDATED
We've refreshed our first-ever NETWise podcast, previously entitled "NETs 101."
Maybe you’ve been recently diagnosed or perhaps you’re a longtime patient. Maybe someone you care about has neuroendocrine cancer. In any case, you probably have questions. What exactly is this disease? What is it doing in your body right now? And what should you be doing about it? This episode will help you find answers to those questions. We speak with some of the leading experts on neuroendocrine tumors from all around the world, and you’ll hear NET patients share their experiences.
| |
Survivorship & "Scanxiety"
June is National Cancer Survivorship Month when we recognize all neuroendocrine cancer survivors and those who have supported them along the way. NETRF is committed to helping you in your survivorship journey through our NET Thrivership resources.
Often, part of a neuroendocrine cancer journey requires periodic scanning and imaging. For this month’s NET Thrivership Series, our Director of Patient Education, Jessica Thomas, talks about “scanxiety” as a real thing one may experience. Learn tools and resources to help you as you prepare for scans, during a scan, and while awaiting your results.
| |
NIH Clinical Trial Evaluates New Drug Conjugate for NETs & NECs
A new first-in-human clinical trial at the National Institutes of Health in Bethesda, Maryland, is exploring the use of an antibody-drug conjugate (ADC), ADCT-701, in adults with neuroendocrine neoplasms (NENs), which include neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs).
ADCs are a form of targeted cancer therapy consisting of an antibody linked to a drug through a connector called a linker. This design allows ADCs to selectively target tumor cells while sparing healthy tissue. The antibody component of an ADC binds specifically to cancer cells, allowing the drug to be internalized and exert its cytotoxic effects, killing the cancer cell.
The Phase I clinical trial aims to determine the maximum tolerated dose of the humanized antibody ADCT-701 in participants with neuroendocrine neoplasms or malignant adrenocortical carcinoma. ADCT-701 targets a specific protein (called the Delta-like non-canonical Notch ligand 1) expressed in many NENs. Although multiple ADCs have been approved for various cancers, none have been approved for neuroendocrine cancers thus far.
Up to 70 participants will be enrolled over a maximum of 10 dose levels. Read more here.
| |
|
Accelerating Discoveries: A 33% Surge in 2024 NETRF Grant Applications Signals Momentum in Neuroendocrine Cancer Research
Exciting News! The 2024 NETRF Grant Cycle is in full swing, and we're thrilled to report a remarkable 33% increase in submissions. This increase is a testament to the global recognition of NETRF's efforts and the widespread interest in investigating neuroendocrine cancer. Dive deeper into our grants process, exploring the journey from idea to breakthrough. And, join us in our mission to fund groundbreaking studies that hold the potential to revolutionize treatments and lead us closer to cures. Read more here.
| |
Thank You, Katherine's Light Foundation!
A heartfelt thank you to Katherine's Light Foundation for hosting an amazing all-day music festival in memory of Katherine Mueller on June 15 at the Severna Park Taphouse in Severna Park, Maryland. With over 300 attendees, the event was a huge success, featuring silent and live auctions, raffles, live music, friendship, and laughter.
Katherine Mueller’s legacy of kindness and fortitude shines brightly through your efforts. The $50,000 raised will significantly support NETRF, with the goal of sponsoring a Pilot Award.
Your dedication and hard work are deeply appreciated. Together, we are making a difference. Thank you for your unwavering commitment and generosity!
| |
Attend an Event in Your Community
Below are some upcoming community events happening to support NETRF.
June 21: The Queenan family hosts a golf tournament in memory of Carolyn Queenan at the Hyannis Golf Club, Hyannis, Massachusetts.
September 20: Moonlight Walk in memory of Julie Seltzer-Firsty in Palo Alto, California.
October 19: Sheryl Strong Fundraiser at the Northridge Country Club, Fair Oaks, California, hosted by Jim Jungsten.
On November 10, 2024, World NET Cancer Day, Bill Thach (pictured above) is running an ultramarathon to raise money for NETRF. Read his incredible story of resilience and determination here.
We will share more details and registration links about these upcoming events on our social channels and in upcoming E-Updates.
| |
Special thanks to ITM, Boehringer Ingelheim & Curium for their support of this E-update.
| |
|
|
|
|
